BC Extra | Sep 14, 2019
Company News

Sept. 13 Company Quick Takes: FDA issues warning on CDK4/6 drugs; plus Castle Creek to buy Fibrocell and Eidos rebuffs BridgeBio

FDA warns of lung inflammation for CDK4/6 drugs  FDA issued a warning Friday that marketed CDK4/6 breast cancer drugs have been associated with a severe but rare risk of lung inflammation. In a review of...
BC Extra | Aug 23, 2019
Company News

Management tracks: Erasca, Frequency, PerkinElmer, CytomX, Infinity and more

Erasca Inc. (San Diego, Calif.) promoted Chief Business Officer Gary Yeung to chief operating and financial officer and hired David Chacko to take over the CBO role. Chacko was a principal at investment firm Versant...
BC Week In Review | Apr 19, 2019
Company News

Castle Creek gets U.S. rights to market Fibrocell's skin disease cell therapy

Castle Creek will pay $7.5 million up front for an exclusive license to commercialize Fibrocell's FCX-007 in the U.S. FCX-007 is a gene-modified autologous fibroblast that carries collagen type VII (COL7A1) to treat recessive dystrophic...
BC Innovations | Mar 22, 2018
Translation in Brief

Switching scleroderma

While existing treatment options for localized scleroderma target inflammation, Fibrocell Science Inc. (NASDAQ:FCSC) and partner Intrexon Corp. (NYSE:XON) plan to enter the clinic next half with FCX-013, a therapy that could reverse fibrosis in patients...
BioCentury | Jan 13, 2018
Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
BC Week In Review | Nov 30, 2017
Clinical News

Fibrocell reports Phase I/II data for FCX-007 in epidermolysis bullosa

In September, Fibrocell Science Inc. (NASDAQ:FCSC) reported interim data from a Phase I/II trial in 3 patients with recessive dystrophic epidermolysis bullosa (EB) showing that a single intradermal injection of FCX-007 led to >75% wound...
BC Extra | Nov 9, 2017
Preclinical News

LAMB3 gene therapy successfully treats epidermolysis bullosa

In a paper published in Nature , researchers from Ruhr University Bochum and colleagues described the successful regeneration and engraftment of almost the entire epidermis of a patient with junctional epidermolysis bullosa (JEB) using laminin beta...
BC Week In Review | Jun 15, 2017
Clinical News

Fibrocell's gene therapy gets rare pediatric disease designation for localized scleroderma

FDA granted rare pediatric disease designation to FCX-013 (GM-HDF-COL7) from Fibrocell Science Inc. (NASDAQ:FCSC) to treat moderate to severe localized scleroderma. In 4Q17, Fibrocell plans to submit an IND to FDA for FCX-013, which also...
BC Week In Review | Mar 9, 2017
Financial News

Fibrocell completes private placement

On March 7, cell and gene therapy company Fibrocell Science Inc. (NASDAQ:FCSC) raised $8 million through the sale of 8,000 units at $1,000 in a private placement to existing investors. Each unit comprises a share...
BC Week In Review | Sep 12, 2016
Financial News

Fibrocell completes private placement of convertible notes and warrants

Fibrocell Science Inc. (NASDAQ:FCSC), Exton, Pa.   Business: Gene/Cell therapy, Dermatology, Autoimmune   Date completed: 2016-09-08   Type: Private placement of convertible notes and warrants   Raised: $18.1 million   Shares outstanding prior: 43.9 million...
Items per page:
1 - 10 of 145
BC Extra | Sep 14, 2019
Company News

Sept. 13 Company Quick Takes: FDA issues warning on CDK4/6 drugs; plus Castle Creek to buy Fibrocell and Eidos rebuffs BridgeBio

FDA warns of lung inflammation for CDK4/6 drugs  FDA issued a warning Friday that marketed CDK4/6 breast cancer drugs have been associated with a severe but rare risk of lung inflammation. In a review of...
BC Extra | Aug 23, 2019
Company News

Management tracks: Erasca, Frequency, PerkinElmer, CytomX, Infinity and more

Erasca Inc. (San Diego, Calif.) promoted Chief Business Officer Gary Yeung to chief operating and financial officer and hired David Chacko to take over the CBO role. Chacko was a principal at investment firm Versant...
BC Week In Review | Apr 19, 2019
Company News

Castle Creek gets U.S. rights to market Fibrocell's skin disease cell therapy

Castle Creek will pay $7.5 million up front for an exclusive license to commercialize Fibrocell's FCX-007 in the U.S. FCX-007 is a gene-modified autologous fibroblast that carries collagen type VII (COL7A1) to treat recessive dystrophic...
BC Innovations | Mar 22, 2018
Translation in Brief

Switching scleroderma

While existing treatment options for localized scleroderma target inflammation, Fibrocell Science Inc. (NASDAQ:FCSC) and partner Intrexon Corp. (NYSE:XON) plan to enter the clinic next half with FCX-013, a therapy that could reverse fibrosis in patients...
BioCentury | Jan 13, 2018
Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
BC Week In Review | Nov 30, 2017
Clinical News

Fibrocell reports Phase I/II data for FCX-007 in epidermolysis bullosa

In September, Fibrocell Science Inc. (NASDAQ:FCSC) reported interim data from a Phase I/II trial in 3 patients with recessive dystrophic epidermolysis bullosa (EB) showing that a single intradermal injection of FCX-007 led to >75% wound...
BC Extra | Nov 9, 2017
Preclinical News

LAMB3 gene therapy successfully treats epidermolysis bullosa

In a paper published in Nature , researchers from Ruhr University Bochum and colleagues described the successful regeneration and engraftment of almost the entire epidermis of a patient with junctional epidermolysis bullosa (JEB) using laminin beta...
BC Week In Review | Jun 15, 2017
Clinical News

Fibrocell's gene therapy gets rare pediatric disease designation for localized scleroderma

FDA granted rare pediatric disease designation to FCX-013 (GM-HDF-COL7) from Fibrocell Science Inc. (NASDAQ:FCSC) to treat moderate to severe localized scleroderma. In 4Q17, Fibrocell plans to submit an IND to FDA for FCX-013, which also...
BC Week In Review | Mar 9, 2017
Financial News

Fibrocell completes private placement

On March 7, cell and gene therapy company Fibrocell Science Inc. (NASDAQ:FCSC) raised $8 million through the sale of 8,000 units at $1,000 in a private placement to existing investors. Each unit comprises a share...
BC Week In Review | Sep 12, 2016
Financial News

Fibrocell completes private placement of convertible notes and warrants

Fibrocell Science Inc. (NASDAQ:FCSC), Exton, Pa.   Business: Gene/Cell therapy, Dermatology, Autoimmune   Date completed: 2016-09-08   Type: Private placement of convertible notes and warrants   Raised: $18.1 million   Shares outstanding prior: 43.9 million...
Items per page:
1 - 10 of 145